natgillin/translations-raw huggingface dataset:
Since hypotension may occur during MabThera administration, consideration should be given to withholding anti-hypertensive medicines 12 hours prior to the MabThera infusion. 
Ker se med aplikacijo zdravila MabThera lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo zdravila MabThera bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
A total of 1078 patients responded to induction therapy, of which 1018 were randomised to MabThera maintenance therapy (n=505) or observation (n=513). 
Na indukcijsko zdravljenje se je odzvalo 1.078 bolnikov, od teh jih je bilo 1.018 randomiziranih v vzdrževalno zdravljenje z zdravilom
• skin rashes, including acne or spots 
· kožni izpuščaji, vključno z aknami ali lisami, · pordevanje ali rdečina kože,
NAME OF THE MEDICINAL PRODUCT MabThera 1600 mg solution for subcutaneous injection 
IME ZDRAVILA MabThera 1600 mg raztopina za podkožno injiciranje
Do not take MabThera if: 
Kaj morate vedeti, preden boste uporabili zdravilo MabThera Ne uporabljajte zdravila MabThera, če:
NAME OF THE MEDICINAL PRODUCT MabThera 1400 mg solution for subcutaneous injection 
IME ZDRAVILA MabThera 1400 mg raztopina za podkožno injiciranje
InSABRINA, severe administration-related reactions (grade≥3) were reported in two patients (2%) following administration of MabThera subcutaneous formulation. 
V preskušanju SABRINA so pri dveh bolnikih (2 %) po uporabi podkožne oblike zdravila MabThera zabeležili hude reakcije (≥ 3. stopnje), povezane z dajanjem zdravila.
The incidence of infusion-related symptoms decreased substantially with subsequent infusions and is <1% of patients by the eighth cycle of MabThera (containing) treatment. 
Incidenca simptomov in znakov, povezanih z infuzijo, se je z nadaljnjimi infuzijami precej zmanjšala in je bila do osmega cikla zdravljenja z zdravilom MabThera < 1 %.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 500 mg concentrate for solution for infusion Rituximab 
IME ZDRAVILA IN POT(I) UPORABE MabThera 500 mg koncentrat za raztopino za infundiranje rituksimab i.v.
None of the 99 MabThera-treated patients were ADA positive at screening. 
Ob presejanju ni imel pozitivnega izvida ADA nobeden od 99 bolnikov, zdravljenih z zdravilom MabThera.
Limited information from one study in relapsed/refractory CLL patients suggests that MabThera treatment may also worsen the outcome of primary hepatitis B infections. 
Omejeni podatki iz ene študije pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, kažejo, da lahko zdravljenje z zdravilom MabThera poslabša tudi izid primarnih okužb z virusom hepatitisa B. Pri vseh bolnikih je treba pred začetkom zdravljenja z zdravilom MabThera narediti presejalni test na virus hepatitisa B. To vključuje najmanj določanje statusa HBsAg in HBcAb, ki ju lahko dopolnimo z ostalimi primernimi označevalci v skladu z lokalnimi smernicami.
Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of MabThera. 
Pred uporabo zdravila MabThera mora bolnik vedno dobiti premedikacijo, ki obsega antipiretik in antihistaminik, npr. paracetamol in difenhidramin.
Each vial contains 1400 mg/11.7 mL rituximab. 
1 viala vsebuje 1400 mg/11,7 ml rituksimaba.
InSparkThera, no severe administration-related reactions were reported. 
Resnih neželenih reakcij, povezanih z infuzijo, niso opazili.
Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential must employ effective contraceptive methods during and for 12 months after treatment with MabThera. 
Zato morajo ženske v rodni dobi med zdravljenjem z zdravilom MabThera in še 12 mesecev po njem uporabljati učinkovita kontracepcijska sredstva.
MabThera should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3). 
Zdravila MabThera se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo,
The recommended dosage of MabThera for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids. 
Priporočeni odmerek zdravila MabThera za zdravljenje navadnega pemfigusa je 1000 mg v intravenski infuziji, ki ji čez dva tedna sledi druga intravenska infuzija 1000 mg; uporablja se v kombinaciji z glukokortikoidi, katerih odmerke postopoma zmanjšujemo.
Table 9 Maintenance phase: overview of efficacy results MabThera vs. observation (28 months median observation time) Efficacy Parameter 
MabThera v primerjavi z opazovanjem (mediana časa opazovanja 28 mesecev)
Similarly, a good to moderate European League Against Rheumatism (EULAR) response was achieved by significantly more MabThera treated patients treated with MabThera and methotrexate compared to patients treated with methotrexate alone (Table 12). 
Rheumatism) doseglo pomembno več bolnikov, ki so se zdravili z zdravilom MabThera in metotreksatom, kakor bolnikov, ki so se zdravili samo z metotreksatom (preglednica 12).
Table 3 Treatment of relapsed/refractory chronic lymphocytic leukaemia -overview of efficacy results for MabThera plus FC vs. FC alone (25.3 months median observation time) Efficacy Parameter 
Zdravljenje kronične limfocitne levkemije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje - pregled rezultatov o učinkovitosti za zdravilo MabThera v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC (mediana opazovanja 25,3 meseca)
Co-administration with methotrexate had no effect on the pharmacokinetics of MabThera in rheumatoid arthritis patients. 
Sočasna uporaba metotreksata pri bolnikih z revmatoidnim artritisom ni vplivala na farmakokinetiko zdravila MabThera.
At that time, and within a maximum of 1 month after the last cyclophosphamide pulse, patients were randomly assigned to receive either MabThera (two 500 mg IV infusions separated by two weeks (on Day 1 and Day 15) followed by 500 mg IV every 6 months for 
Takrat in znotraj največ 1 meseca po zadnjem pulzu ciklofosfamida so bolnike randomizirali ali na prejemanje zdravila MabThera (dve 500-mg intravenski infuziji v presledku dveh tednov (1. in 15. dan) in nato 500 mg intravensko vsakih 6 mesecev v obdobju 18 mesecev) ali na prejemanje azatioprina (peroralno v odmerku 2 mg/kg/dan 12 mesecev, nato 1,5 mg/kg/dan 6 mesecev in nazadnje 1 mg/kg/dan 4 mesece (prenehanje zdravljenja po teh 22 mesecih)).
MabThera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. 
Zdravilo MabThera je v kombinaciji s kemoterapijo indicirano za zdravljenje bolnikov s kronično limfocitno levkemijo, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 1600 mg solution for subcutaneous injection Rituximab subcutaneous 
IME ZDRAVILA IN POT(I) UPORABE MabThera 1600 mg raztopina za podkožno injiciranje rituksimab subkutano
• respiratory failure 
· odpoved dihanja
Table 2a First--line treatment of chronic lymphocytic leukaemia Overview of efficacy results for MabThera plus FC vs. FC alone - 48.1 months median observation time Efficacy Parameter 
Pregled rezultatov o učinkovitosti za zdravilo MabThera v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC - mediana opazovanja 48,1 meseca
MabThera 1600 mg solution for subcutaneous injection rituximab 
MabThera 1600 mg raztopina za podkožno injiciranje rituksimab
Patients in both arms received 1000mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day). 
Bolniki v obeh terapevtskih skupinah so prejemali 1000 mg metilprednizolona (ali drugega glukokortikoida v enakovrednem odmerku) na dan pulzno intravensko (i.v.)
This card tells you: 
Priporočeni odmerek je:
What MabThera 1600 mg solution for subcutaneous injection looks like and contents of the pack 
Izgled zdravila MabThera 1600 mg raztopina za podkožno injiciranje in vsebina pakiranja
Maintenance treatment with MabThera led to a clinically relevant and statistically significant improvement in the primary endpoint, PFS, (time from maintenance randomisation to relapse, disease progression or death) when compared to observation alone (p< 0.0001 log-rank test).The median PFS was 42.2 months in the MabThera maintenance arm compared to 14.3 months in the observation arm. 
Vzdrževalno zdravljenje z zdravilom MabThera je klinično pomembno in statistično značilno izboljšalo primarni cilj - preživetje brez napredovanja bolezni (progression free survival - PFS) (čas od randomizacije v vzdrževalno zdravljenje do ponovitve bolezni, napredovanja bolezni ali smrti) v primerjavi z opazovano skupino (p < 0,0001, test log-rang).
MabThera is indicated in adults in combination with chemotherapy for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL). 
Zdravilo MabThera je v kombinaciji s kemoterapijo indicirano za zdravljenje odraslih bolnikov s kronično limfocitno levkemijo (KLL), ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 1400 mg solution for subcutaneous injection Rituximab subcutaneous 
IME ZDRAVILA IN POT(I) UPORABE MabThera 1400 mg raztopina za podkožno injiciranje rituksimab subkutano
Table 2 Efficacy results for SABRINA (BO22334) (Intent to Treat Population) Pooled Stages 1 & 2 N = 410 
Rezultati učinkovitosti za preskušanje SABRINA (BO22334) (populacija, ki so jo nameravali zdraviti)
Since hypotension may occur during MabThera administration, consideration should be given to withholding anti-hypertensive medicines 12 hours prior to giving MabThera. 
Ker se med aplikacijo zdravila MabThera lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred dajanjem zdravila MabThera bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
For the 60 re-treatments on study, the ORR was 38% (CI95% 26% - 51%; 10% CR, 28% PR) with a projected median TTP for responding patients of 17.8 months (range 5.4 - 26.6). 
Za 60 ponovnih zdravljenj je bil celokupen odgovor na zdravljenje 38 % (95-% interval zaupanja 26-51 %; 10 % popoln odgovor, 28 % delni odgovor).
MabThera 1400 mg solution for subcutaneous injection rituximab 
MabThera 1400 mg raztopina za podkožno injiciranje rituksimab
The European Medicines Agency has waived the obligation to submit the results of studies with rituximab in all subsets of the paediatric population with CLL. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev izsledkov študij z rituksimabom za vse podskupine pediatrične populacije s folikularnimi limfomi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Outcome† 
PRILOGA I
A small number of spontaneous and literature cases of hypogammaglobulinaemia have been observed in paediatric patients treated with MabThera, in some cases severe and requiring long-term immunoglobulin substitution therapy. 
Ta je bila v nekaj primerih huda in je zahtevala dolgotrajno nadomestno zdravljenje z imunoglobulini.
The serum MabThera Cmax at Cycle 6 was lower in the subcutaneous arm than the intravenous, with geometric mean (CV%) values of 202 (36.1) μg/mL and 280 (24.6) μg/mL with the resulting geometric mean ratio (Cmax, SC/Cmax, IV) of 0.719 (90% CI: 0.653, 0.792). 
Geometrična sredina (KV %) je bila s podkožno obliko 202 (36,1) µg/ml in z intravensko 280 (24,6) µg/ml; razmerje geometričnih sredin (Cmax s.c./Cmax i.v.)
Regular full blood counts, including neutrophil and platelet counts, should be performed during MabThera therapy. 
Med zdravljenjem z zdravilom MabThera je treba redno kontrolirati celotno krvno sliko, vključno s številom nevtrofilcev in trombocitov.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 100 mg concentrate for solution for infusion Rituximab 
IME ZDRAVILA IN POT(I) UPORABE MabThera 100 mg koncentrat za raztopino za infundiranje rituksimab i.v.
lung infiltration, 
infiltracija pljuč
MabThera subcutaneous formulation contains recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the dispersion and absorption of co-administered substances when administered subcutaneously. 
Podkožna oblika zdravila MabThera vsebuje rekombinantno humano hialuronidazo (rHuPH20).
where the frequency count was based only on severe (≥ grade 3 NCI common toxicity criteria) reactions. 
Pri vsakem izrazu so pri določitvi pogostnosti upoštevali neželene učinke vseh stopenj (od blage do hude), razen za izraze, označene s "+", kjer so pri določitvi pogostnosti upoštevali le hude neželene učinke (≥ 3. stopnja po lestvici skupnih meril toksičnosti Nacionalnega inštituta za raka (NCI common toxicity criteria)).
• If you are having MabThera with chemotherapy MabThera will be given to you on the same day as your chemotherapy. 
Koliko zdravila boste dobili in kako pogosto · Zdravilo MabThera boste dobili isti dan kot kemoterapijo.
MabThera treatment. 
Shranjevanje zdravila MabThera
• skin disorders such as itching, hives, and benign lumps 
· spremembe razpoloženja, kot sta razdražljivost in depresija, · bolezni kože, kot so srbenje, koprivnica in benigne bule,
Hypogammaglobulinaemia (IgG or IgM below the lower limit of normal) has been observed in RA patients treated with MabThera. 
Pri bolnikih z revmatoidnim artritisom, ki so jih zdravili z zdravilom MabThera, so opazili hipogamaglobulinemijo (IgG ali IgM pod spodnjo mejo normale).
respiratory failure4, 
+odpoved več organov4
• muscle problems - such as tight muscles, joint or muscle pain, back and neck pain 
· koprivnica, močnejše znojenje, nočno znojenje · težave z mišicami - na primer napete mišice, bolečine v sklepih ali mišicah, bolečine v hrbtu in vratu
Table 13 Radiographic outcomes at 1 year (mITT population) Placebo+MTX MabThera+MTX 2 × 1000 mg 
Radiološki izidi po 1 letu v študiji 1 (populacija, ki so jo nameravali zdraviti) Placebo + metotreksat
STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 10 mg/mL rituximab. 
1 viala vsebuje 10 mg/ml rituksimaba.
The overall rate of infection was approximately 94 per 100 patient years in MabThera treated patients. 
Okužbe Pri bolnikih, ki so se zdravili z zdravilom MabThera, je bil celokupni delež okužb približno 94 na
There are no data on the safety of MabThera in patients with moderate heart failure (NYHA class III) or severe, uncontrolled cardiovascular disease. 
Podatkov o varnosti zdravila MabThera pri bolnikih z zmernim srčnim popuščanjem (III. razred
You must also do this for 12 months after your last treatment with MabThera. 
Učinkovito kontracepcijsko zaščito morate nadaljevati še 12 mesecev po zadnjem odmerku zdravila MabThera.
The safety of immunisation with live viral vaccines, following MabThera therapy has not been studied for NHL and CLL patients and vaccination with live virus vaccines is not recommended. 
Hodgkinovim limfomom (NHL) in KLL niso proučevali in cepljenje z živimi virusnimi cepivi ni priporočljivo.
MabThera subcutaneous formulation should be injected subcutaneously into the abdominal wall and never into areas where the skin is red, bruised, tender, hard or areas where there are moles or scars. 
Zdravila se nikdar ne sme injicirati v predele kože, ki je pordela, podpluta, občutljiva, zatrdela; prav tako se ga ne sme injicirati v predele, kjer so na koži znamenja ali brazgotine.
MabThera 100 mg concentrate for solution for infusion MabThera 500 mg concentrate for solution for infusion rituximab 
Navodilo za uporabo MabThera 100 mg koncentrat za raztopino za infundiranje MabThera 500 mg koncentrat za raztopino za infundiranje rituksimab
The recommended dosage of MabThera in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. 
Kronična limfocitna levkemija Priporočeni odmerek zdravila MabThera v kombinaciji s kemoterapijo pri bolnikih, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila, je 375 mg/m2 telesne površine, ki ga damo na dan 0 prvega cikla zdravljenja, v naslednjih ciklih zdravljenja pa dajemo 1. dan 500 mg/m2 telesne površine, skupaj 6 ciklov.
Localised candida infections as well as Herpes zoster were reported at a higher incidence in the MabThera-containing arm of randomised studies. 
V randomiziranih študijah so pri bolnikih, ki so prejemali zdravilo MabThera, opažali večjo incidenco lokaliziranih okužb s kandido in herpesom zostrom.
After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/refractory follicular lymphoma when compared to CHOP (see Table 8). 
mesečnega opazovanja izid zdravljenja pomembno izboljšal v primerjavi s skupino CHOP (glejte preglednico 8).
• swelling of the hands or ankles 
· otekanje rok ali gležnjev.
B lymphocytes are involved in the cause of these conditions. 
V nastanek teh bolezni so vpleteni limfociti B. e)
Baseline tumour load was available only in trial BO22334. 
Manjkajočih vrednosti sospremenljivk ni bilo; izjema je izhodiščno število celic B. Izhodiščno tumorsko breme je bilo na voljo le v preskušanju BO22334.
Nervous system disorders paraesthesia, hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety 
Bolezni živčevja parestezije, hipestezija, agitiranost,
The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector functions to mediate B cell lysis. 
Domena rituksimaba Fab se veže na antigen CD20 na B-limfocitih in prek domene Fc sproži imunska dogajanja, ki privedejo do razgradnje celic B. Mogoča mehanizma celične razgradnje sta od komplementa odvisna citotoksičnost (complement-dependent cytotoxicity - CDC), ki je posledica vezave C1q, in od protiteles odvisna celična citotoksičnost (antibody-dependent cellular cytotoxicity
MabThera, administered as an intravenous infusion at a dose of 375 mg/m2 at weekly intervals for 4 
MabThera, ponovno prejelo 4 odmerke po 375 mg/m2 zdravila MabThera v obliki intravenske infuzije enkrat na teden.
Mean Cmax for serum rituximab following first infusion was 170 to 175 µg/mL for 2 x 500 mg dose and 317 to 370 µg/mL for 2 x 1000 mg dose. 
170 do 175 mg/ml za 2 x 500 mg odmerek ter 317 do 370 mg/ml za 2 x 1000 mg odmerek.
• Weight loss 
· siljenje na bruhanje
Bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia interstitial lung disease7 
bolečina v prsnem košu, dispneja, izrazitejši kašelj, rinitis astma, bronchiolitis obliterans,
For retreatment with MabThera monotherapy for patients who have responded to previous treatment with MabThera monotherapy for relapsed/refractory follicular lymphoma, the recommended dose is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for four weeks 
Priporočeni odmerek zdravila MabThera za ponovno samostojno zdravljenje bolnikov s folikularnim limfomom, ki so se odzvali na prejšnje samostojno zdravljenje z zdravilom MabThera po tem, ko se na predhodno zdravljenje niso odzvali ali se je pri njih bolezen ponovila, je: 375 mg/m2 telesne površine v obliki intravenske infuzije enkrat na teden 4 tedne (glejte poglavje 5.1).
6 Contents of the pack and other information 
5 Shranjevanje zdravila MabThera Vsebina pakiranja in dodatne informacije
• producing more tears, tear duct problems, inflamed eye (conjunctivitis) 
· omotica ali občutek tesnobe · močnejše solzenje, težave s solznimi izvodili, vnetje očesa (konjunktivitis) · zvonjenje v ušesih, bolečine v ušesu
Closely monitor patients with pre-existing cardiac conditions and those who experienced prior cardiopulmonary adverse reactions. 
Opaženi v glavnem pri bolnikih z obstoječimi boleznimi srca in/ali kardiotoksično kemoterapijo ter pretežno v zvezi z reakcijami, povezanimi z infuzijo.
The recommended dose of MabThera monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for four weeks. 
in IV. stadijem folikularnih limfomov, ki so neodzivni na kemoterapijo ali se je pri njih bolezen po kemoterapiji drugič ali že večkrat ponovila, je: 375 mg/m2 telesne površine v obliki intravenske infuzije enkrat na teden 4 tedne.
In the induction of remission clinical trial, at 6 months, in the MabThera group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline had low IgA, IgG and IgM levels, respectively, compared to 25%, 50% and 46% in the cyclophosphamide group. 
V kliničnem preskušanju indukcije remisije so po 6 mesecih pri bolnikih, ki so imeli izhodiščno normalne ravni imunoglobulinov, med prejemniki zdravila MabThera zabeležili nizke IgA, IgG in
• If you get any side effects talk to your doctor, pharmacist or nurse. 
· Če opazite kateri koli neželeni učinek se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
The recommended dose of MabThera subcutaneous formulation used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 1400 mg once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 administrations in total). 
· Ponovitev folikularnih limfomov ali neodzivna bolezen Priporočeni odmerek zdravila MabThera za vzdrževalno zdravljenje bolnikov s ponovitvijo folikularnih limfomov ali neodzivno boleznijo, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 3 mesece (z začetkom 3 mesece po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 8 infuzij).
Bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia lung disease7 respiratory failure4, 
bolečina v prsnem košu, dispneja, izrazitejši kašelj, rinitis astma, bronhiolitis obliterans,
You should also tell them about your MabThera treatment. 
Povejte, da se zdravite z zdravilom MabThera.
Mean terminal elimination half-life ranged from 15 to 16 days for the 2 x 500 mg dose group and 17 to 21 days for the 2 × 1000 mg dose group. 
x 500 mg odmerek ter 17 do 21 dni za 2 x 1000 mg odmerek.
MabThera is used for the treatment of patients with moderate to severe pemphigus vulgaris. 
navadnega pemfigusa Zdravilo MabThera se uporablja za zdravljenje bolnikov z zmernim do hudim navadnim pemfigusom.
The recommended dose of MabThera in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: first cycle with MabThera intravenous formulation 375 mg/m2 
Priporočeni odmerek zdravila MabThera v kombinaciji s kemoterapijo za indukcijsko zdravljenje bolnikov s folikularnimi limfomi, ki se predhodno še niso zdravili ali se na prejšnje zdravljenje niso odzvali ali se jim je bolezen ponovila, je: prvi cikel z intravensko obliko zdravila MabThera 375 mg/m2 telesne površine, nato nadaljnji cikli s podkožno obliko zdravila MabThera, injiciranega v fiksnem odmerku 1400 mg na cikel do 8 ciklov.
The highest risk of experiencing an administration related reaction is generally observed at cycle one. 
V prvem ciklusu zdravljenja je na splošno največje tveganje za pojav reakcij, povezanih z dajanjem zdravila.